Compass Therapeutics, Inc. (NASDAQ:CMPX)
| Market Cap | 177.58M-74.7% |
| Revenue (ttm) | 0 |
| Net Income | -73.45M-18.4% |
| EPS | -0.41+7.0% |
| Shares Out | 180.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 825,787.435 |
| Open | 1.01 |
| Previous Close | 1.02 |
| Day's Range | 0.97 - 1.01 |
| 52-Week Range | 0.83 - 6.88 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 4.67(+373.58%) |
| Earnings Date | Nov 4, 2026 |
Compass Therapeutics, Inc. has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
About CMPX
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CMPX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CMPX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CMPX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CMPX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CMPX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CMPX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CMPX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $10.02M |
| XBIState Street SPDR S&P Biotech ETF | $5.03M |
| VXFVanguard Extended Market ETF | $4.35M |
| IWMiShares Russell 2000 ETF | $3.60M |
| VTWOVanguard Russell 2000 ETF | $1.80M |
| FESMFidelity Enhanced Small Cap ETF | $1.62M |
Estimated from each fund’s disclosed top holdings × AUM
CMPX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CMPX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score